cagrilintide fda vs Tirzepatide Compared Cagrilintide (10 mg) | GLP-1

Any dosing figures below describe clinical-trial protocols or, for cagrilintide, research conventions with no approved label not a personal protocol

Independent analysis is vital to ensuring the quality and authenticity of your research peptides

Tirzepatide carries an FDA boxed warning for thyroid C-cell tumors plus warnings for pancreatitis, gallbladder disease, and hypoglycemia with insulin secretagogues

PMID 38753454

How long does each one stay in the body

[4] In the SURMOUNT-1 obesity trial, a 72-week placebo-controlled study in 2,539 adults with obesity (without diabetes), mean weight change was 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses versus 3.1% for placebo